Management of Elevated LDL Cholesterol in Pregnancy

Primary Management Approach

The American College of Cardiology recommends intensive lifestyle interventions, including a heart-healthy diet and increased physical activity, as the foundation of treatment for elevated LDL cholesterol in pregnancy 1, 2
The American Heart Association suggests that dietary and lifestyle measures should be optimized before, during, and after pregnancy to manage elevated LDL cholesterol 1

Bile acid sequestrants, such as cholestyramine, colestipol, and colesevelam, are considered safe for use during pregnancy due to their non-systemic absorption and are recommended by the National Lipid Association 1, 2, 3
The European Atherosclerosis Society recommends initiating bile acid sequestrants 3 months before planned pregnancy and continuing throughout pregnancy and lactation 1, 3

The American College of Cardiology recommends that women with homozygous familial hypercholesterolemia (HoFH) continue or initiate lipoprotein apheresis during pregnancy, especially those with established atherosclerotic cardiovascular disease (ASCVD) 1, 2
The National Lipid Association suggests that continued use of statin therapy may be considered in HoFH patients with clinical ASCVD after the first trimester if LDL-C goals are not achieved and apheresis is unavailable 1

The American Heart Association recommends avoiding ezetimibe, PCSK9 inhibitors, bempedoic acid, fibrates, and niacin during pregnancy due to insufficient safety data or potential fetal risk 2, 4

The National Lipid Association recommends monitoring all pregnant women for significant elevations in LDL-C and triglycerides, recognizing that progressive rises are physiologic 2
The American College of Cardiology suggests that routine lipid monitoring is generally not indicated unless results will change management, such as in HoFH patients 1

The American Heart Association recommends resuming lipid-lowering therapy after completion of breastfeeding, while bile acid sequestrants remain the only safe pharmacological option during breastfeeding if treatment is necessary 2, 3, 5

The American Diabetes Association recommends that for women with homozygous familial hypercholesterolemia and established atherosclerotic cardiovascular disease, lipoprotein apheresis should be continued or initiated during pregnancy, particularly for those with established atherosclerotic cardiovascular disease 6, 7
For women at highest cardiovascular risk, consideration of continuing statin therapy during pregnancy may be warranted when the cardiovascular risk of discontinuation outweighs potential fetal concerns, according to the American Diabetes Association 6, 7
A meta-analysis of pravastatin showed reduction in preeclampsia, premature birth, and neonatal intensive care unit admissions, as reported by the American Diabetes Association 6, 7
Statins did not increase teratogenic effects in women with familial hypercholesterolemia in limited studies, as reported by the American Diabetes Association 6, 7
Preconception counseling for women on lipid-lowering therapy is essential, and contraception is necessary when using medications with unknown or known pregnancy risks, as recommended by the American Diabetes Association 6, 7